Evidence map›Paper›PMID 38304784›Full record

ArticleHeliyon2024

Shamsa Hilal Saleh Alanazi, Muhammad Farooq Khan, Anas M Alazami, Almohannad Baabbad, Mohammad Ahmed Wadaan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shamsa Hilal Saleh AlanaziBioproducts Research Chair, Department of Zoology, College of Science, King Saud University, P.O Box 2455 Riyadh 11451, Kingdom of Saudi Arabia.
Muhammad Farooq KhanBioproducts Research Chair, Department of Zoology, College of Science, King Saud University, P.O Box 2455 Riyadh 11451, Kingdom of Saudi Arabia.
Anas M AlazamiTranslational Genomics Department, Centre for Genomic Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Almohannad BaabbadBioproducts Research Chair, Department of Zoology, College of Science, King Saud University, P.O Box 2455 Riyadh 11451, Kingdom of Saudi Arabia.
Mohammad Ahmed WadaanBioproducts Research Chair, Department of Zoology, College of Science, King Saud University, P.O Box 2455 Riyadh 11451, Kingdom of Saudi Arabia.
King Saud University · SAKing Faisal Specialist Hospital & Research Centre · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite substantial investments in anti-glioblastoma (GBM) drug discovery over the last decade, progress is limited to preclinical stages, with clinical studies frequently encountering obstacles. Angiogenic and histone deacetylase inhibitors (HDACi) have shown profound results in pre-clinical studies. Investigating a multicomponent anti-cancer remedy that disrupts the tumor angiogenic blood vessels and simultaneously disrupts HDACs, while inducing minimal side effects, is critically needed. The crude extracts derived from medicinal plants serve as a renewable reservoir of anti-tumor drugs, exhibiting reduced toxicity compared to chemically synthesized formulations.

Indexed as

Calotropis proceraDanio rerioGlioblastoma multiformeHistone deacetylasesHuman angiogenesis antibody array

Identifiers

PMID38304784
PMCPMC10831610
OpenAlexW4390825858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.